Amongst them, Pinometostat, a first‐in‐class small‐molecule inhibitor targeting the H3K79 methyltransferase DOT1L has been used in a phase 1 clinical trial in MLL leukaemias [39]. This evidence concerns the gene KMT2A and leukemia.